135 related articles for article (PubMed ID: 1383907)
1. [Initial results of hybrid chemotherapy of Hodgkin's disease using COPP/VBA].
Schneider T; Molnár Z; Szántó I; Fleischmann T
Orv Hetil; 1992 Oct; 133(43):2755-7. PubMed ID: 1383907
[TBL] [Abstract][Full Text] [Related]
2. Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: a progress report.
Sagar TG; Chandra A; Raman SG
Med Pediatr Oncol; 2003 Jan; 40(1):66-9. PubMed ID: 12426693
[No Abstract] [Full Text] [Related]
3. [Comparative study of advanced-stage Hodgkin's lymphoma patients treated with either COPP or ABVD drug combinations].
Molnár Z; Fleischmann T
Orv Hetil; 1992 Jun; 133(25):1561-3. PubMed ID: 1383902
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two non-cross-resistant combinations (ABVP/LOPP) with COPP plus bleomycin in the treatment of advanced Hodgkin's disease.
Koza I; Bohunický L; Mociková K; Gyárfás J; Svancárová L; Mardiak J; Spánik S; Fuchsberger P; Thalmeinerová Z; Sufliarsky J
Neoplasma; 1991; 38(6):583-93. PubMed ID: 1722564
[TBL] [Abstract][Full Text] [Related]
5. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
[TBL] [Abstract][Full Text] [Related]
7. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
8. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
9. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of children and adolescents treated with the COPP-ABV hybrid protocol for Hodgkin's disease: balance of risks.
Klumb CE; Carriço MK; de Rezende LM; Byington R; Bordallo MA; Bigni RS; Apa AG; Dobbin JA
Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):628-9. PubMed ID: 17662581
[No Abstract] [Full Text] [Related]
11. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
12. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
Klimo P; Connors JM
Semin Hematol; 1988 Apr; 25(2 Suppl 2):34-40. PubMed ID: 2456621
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin's disease in Indian children: outcome with chemotherapy alone.
Arya LS; Dinand V; Thavaraj V; Bakhshi S; Dawar R; Rath GK; Singh R; Vats TS
Pediatr Blood Cancer; 2006 Jan; 46(1):26-34. PubMed ID: 16161019
[TBL] [Abstract][Full Text] [Related]
14. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
15. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
[TBL] [Abstract][Full Text] [Related]
16. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
17. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
18. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin's disease.
Raina V; Sharma A; Mohanti BK; Kumar R; Dawar R; Rath GK
Natl Med J India; 2003; 16(4):199-203. PubMed ID: 14606767
[TBL] [Abstract][Full Text] [Related]
19. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.
Kelly KM; Hutchinson RJ; Sposto R; Weiner MA; Lones MA; Perkins SL; Massey V;
Ann Oncol; 2002; 13 Suppl 1():107-11. PubMed ID: 12078889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]